YONGIN, South Korea I November 3, 2014 I Green Cross and MOGAM Biotechnology Institute today announced initiation of a Phase I clinical trial in South Korea to evaluate the safety, tolerability and efficacy of its investigational drug GC1118, an epidermal growth factor receptor (EGFR) targeted antibody.
Dysregulation of EGFR is linked to the development and progression of cancer. GC1118 is a novel anti-EGFR monoclonal antibody with different mode of action compared with currently marketed antibodies.
“GC1118 inhibits tumour cells by blocking broad spectrum of EGFR ligand binding, receptor activation and downstream signalling. We anticipate that GC1118 shows superior tumour inhibitory efficacy and different, potentially broader, patient pool, due to its novel mode of action.” stated Jong-hwa Won, Ph. D., Investigator of MOGAM Biotechnology Institute. “GC1118 represents a novel line of targeting EGFR with the great potential to be significant step forward in the treatment of patient with cancer.”
The Phase I clinical trial is an open-label, multi-centre dose escalation trial study to evaluate the safety and tolerability multiple dose of GC1118 in patients with advanced solid tumours.
About Green Cross
Green Cross provides total healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specialises in the development and manufacture of plasma-derivatives, vaccines and recombinant proteins.
About MOGAM Biotechnology Institute
MOGAM, based in Yongin, South Korea, has committed itself to undertaking research that contributes to improving the health of the nation by developing the drugs required to prevent and treat disease. Green Cross established the MOGAM in 1982, based on its success in commercializing hepatitis B vaccines for use in both internal and external markets.
SOURCE: Green Cross
Post Views: 143
YONGIN, South Korea I November 3, 2014 I Green Cross and MOGAM Biotechnology Institute today announced initiation of a Phase I clinical trial in South Korea to evaluate the safety, tolerability and efficacy of its investigational drug GC1118, an epidermal growth factor receptor (EGFR) targeted antibody.
Dysregulation of EGFR is linked to the development and progression of cancer. GC1118 is a novel anti-EGFR monoclonal antibody with different mode of action compared with currently marketed antibodies.
“GC1118 inhibits tumour cells by blocking broad spectrum of EGFR ligand binding, receptor activation and downstream signalling. We anticipate that GC1118 shows superior tumour inhibitory efficacy and different, potentially broader, patient pool, due to its novel mode of action.” stated Jong-hwa Won, Ph. D., Investigator of MOGAM Biotechnology Institute. “GC1118 represents a novel line of targeting EGFR with the great potential to be significant step forward in the treatment of patient with cancer.”
The Phase I clinical trial is an open-label, multi-centre dose escalation trial study to evaluate the safety and tolerability multiple dose of GC1118 in patients with advanced solid tumours.
About Green Cross
Green Cross provides total healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specialises in the development and manufacture of plasma-derivatives, vaccines and recombinant proteins.
About MOGAM Biotechnology Institute
MOGAM, based in Yongin, South Korea, has committed itself to undertaking research that contributes to improving the health of the nation by developing the drugs required to prevent and treat disease. Green Cross established the MOGAM in 1982, based on its success in commercializing hepatitis B vaccines for use in both internal and external markets.
SOURCE: Green Cross
Post Views: 143
